维生素D辅助多西他赛化疗对前列腺癌患者疗效及安全性的Meta分析

Meta-analysis of the efficacy and safety of vitamin D-assisted docetaxel chemotherapy in patients with prostate cancer

目的评价维生素D辅助多西他赛化疗对前列腺癌患者的疗效及安全性。方法采用计算机并配合手工检索PubMed、EMBASE及中国生物医学文献数据库(CBMdisc)、中国期刊全文数据库、万方数据库和相关会议报道的维生素D辅助多西他赛化疗治疗前列腺癌的随机对照试验,搜索截止时间为2019年3月。主要观察指标包括血清前列腺特异性抗原(PSA)应答率、死亡率及副作用。采用STATA12.0软件进行荟萃分析。结果共纳入3项随机对照试验。Meta分析结果显示维生素D辅助多西他赛组和安慰剂组之间PSA应答率(RR=1.21,95%CI:0.99~1.48;P=0.06)无显著性差异;两组之间死亡率(RR=1.05,95%CI:0.81~1.37;P=0.71)无显著性差异。结论本研究显示维生素D辅助多西他赛化疗并未使前列腺癌患者受益,因此不建议将其用于辅助化疗。

ObjectiveTo evaluate the efficacy and safety of vitamin D-assisted docetaxel chemotherapy for prostate cancer.MethodsRandomized controlled trials(RCTs)that evaluated the efficacy of vitamin D-assisted docetaxel chemotherapy for prostate cancer were searched in PubMed,EMBASE,China Biomedical Literature Database(CBMdisc),Chinese Journal Full-text Database,Wanfang Database and related conference proceedings up to March 2019.The primary indicators included prostate specific antigen(PSA)response rate,mortality and side effects.Meta-analysis was performed using STATA12.0 software.ResultsAltogether 3 RCTs were included.Meta-analysis showed that there was no significant difference in PSA response rate(RR=1.21,95%CI:0.99-1.48,P=0.06)and mortality(RR=1.05,95%CI:0.81-1.37,P=0.71)between vitamin D-assisted docetaxel group and placebo group.ConclusionThis study shows that vitamin D-assisted docetaxel chemotherapy does not benefit prostate cancer patients,so it is not recommended for adjuvant chemotherapy.